TY - JOUR AU - Shirachi, R. AU - Shiraishi, H. AU - Tateda, A. AU - Kikuchi, K. AU - Ishida, N. PY - 1978 DA - 1978// TI - Hepatitis "C" antigen in non-a, non-B post-transfusion hepatitis JO - Lancet VL - 2 UR - https://doi.org/10.1016/S0140-6736(78)91567-2 DO - 10.1016/S0140-6736(78)91567-2 ID - Shirachi1978 ER - TY - JOUR AU - Houghton, M. AU - Weiner, A. AU - Han, J. AU - Kuo, G. AU - Choo, Q. L. PY - 1991 DA - 1991// TI - Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease JO - Hepatology VL - 14 UR - https://doi.org/10.1002/hep.1840140227 DO - 10.1002/hep.1840140227 ID - Houghton1991 ER - TY - JOUR AU - Clarke, A. AU - Kulasegaram, R. PY - 2006 DA - 2006// TI - Hepatitis C transmission -- where are we now? JO - Int J STD AIDS VL - 17 UR - https://doi.org/10.1258/095646206775455685 DO - 10.1258/095646206775455685 ID - Clarke2006 ER - TY - JOUR AU - Matthews, G. V. AU - Pham, S. T. AU - Hellard, M. AU - Grebely, J. AU - Zhang, L. AU - Oon, A. AU - Marks, P. AU - van Beek, I. AU - Rawlinson, W. AU - Kaldor, J. M. PY - 2011 DA - 2011// TI - Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C JO - Clin Infect Dis VL - 52 UR - https://doi.org/10.1093/cid/ciq200 DO - 10.1093/cid/ciq200 ID - Matthews2011 ER - TY - JOUR AU - Westbrook, R. H. AU - Dusheiko, G. PY - 2014 DA - 2014// TI - Natural history of hepatitis C JO - J Hepatol VL - 61 UR - https://doi.org/10.1016/j.jhep.2014.07.012 DO - 10.1016/j.jhep.2014.07.012 ID - Westbrook2014 ER - TY - JOUR AU - Wedemeyer, H. AU - Dore, G. J. AU - Ward, J. W. PY - 2015 DA - 2015// TI - Estimates on HCV disease burden worldwide - filling the gaps JO - J Viral Hepat VL - 22 UR - https://doi.org/10.1111/jvh.12371 DO - 10.1111/jvh.12371 ID - Wedemeyer2015 ER - TY - JOUR AU - Innes, H. AU - Goldberg, D. AU - Dillon, J. AU - Hutchinson, S. J. PY - 2015 DA - 2015// TI - Strategies for the treatment of hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? JO - Gut VL - 64 UR - https://doi.org/10.1136/gutjnl-2014-308166 DO - 10.1136/gutjnl-2014-308166 ID - Innes2015 ER - TY - JOUR AU - Ward, J. W. AU - Mermin, J. H. PY - 2015 DA - 2015// TI - Simple, effective, but out of reach? Public health implications of HCV drugs JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMe1513245 DO - 10.1056/NEJMe1513245 ID - Ward2015 ER - TY - JOUR AU - Sulkowski, M. S. AU - Vargas, H. E. AU - Di Bisceglie, A. M. AU - Kuo, A. AU - Reddy, K. R. AU - Lim, J. K. AU - Morelli, G. AU - Darling, J. M. AU - Feld, J. J. AU - Brown, R. S. PY - 2016 DA - 2016// TI - Effectiveness of Simeprevir plus Sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection JO - Gastroenterology VL - 150 UR - https://doi.org/10.1053/j.gastro.2015.10.013 DO - 10.1053/j.gastro.2015.10.013 ID - Sulkowski2016 ER - TY - STD TI - van Katwyk S, Coyle D, Cooper C, Pussegoda K, Cameron C, Skidmore B, Brener S, Moher D, Thavorn K. Transient elastography for the diagnosis of liver fibrosis: a systematic review of economic evaluations. Liver Int. 2017;37(6):851–61 ID - ref10 ER - TY - JOUR AU - Gentile, I. AU - Maraolo, A. E. AU - Niola, M. AU - Graziano, V. AU - Borgia, G. AU - Paternoster, M. PY - 2016 DA - 2016// TI - Limiting the access to direct-acting antivirals against HCV: an ethical dilemma JO - Expert Rev Gastroenterol Hepatol VL - 10 UR - https://doi.org/10.1080/17474124.2016.1234375 DO - 10.1080/17474124.2016.1234375 ID - Gentile2016 ER - TY - JOUR AU - Chhatwal, J. AU - He, T. AU - Lopez-Olivo, M. A. PY - 2016 DA - 2016// TI - Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals JO - Pharmacoeconomics VL - 34 UR - https://doi.org/10.1007/s40273-015-0373-9 DO - 10.1007/s40273-015-0373-9 ID - Chhatwal2016 ER - TY - CHAP PY - 2009 DA - 2009// TI - Systematic Reviews - CRD’s guidance for undertaking reviews in health care BT - Centre for Reviews and Dissemination PB - University of York CY - York ID - ref13 ER - TY - JOUR AU - Philips, Z. AU - Bojke, L. AU - Sculpher, M. AU - Claxton, K. AU - Golder, S. PY - 2006 DA - 2006// TI - Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment JO - Pharmacoeconomics VL - 24 UR - https://doi.org/10.2165/00019053-200624040-00006 DO - 10.2165/00019053-200624040-00006 ID - Philips2006 ER - TY - JOUR AU - Husereau, D. AU - Drummond, M. AU - Petrou, S. AU - Carswell, C. AU - Moher, D. AU - Greenberg, D. AU - Augustovski, F. AU - Briggs, A. H. AU - Mauskopf, J. AU - Loder, E. PY - 2013 DA - 2013// TI - Consolidated health economic evaluation reporting standards (CHEERS) statement JO - Value in health J International Society for Pharmacoeconomics Outcomes Res VL - 16 UR - https://doi.org/10.1016/j.jval.2013.02.010 DO - 10.1016/j.jval.2013.02.010 ID - Husereau2013 ER - TY - STD TI - R Core Team: R: A language and environment for statistical computing. In. Vienna, Austria: R Foundation for Statistical Computing; 2017: URL https://www.r-project.org/. 24 May 2018. UR - https://www.r-project.org/ ID - ref16 ER - TY - JOUR AU - Athanasakis, K. AU - Ferrante, S. A. AU - Kyriopoulos, I. I. AU - Petrakis, I. AU - Hill, M. AU - Retsa, M. P. AU - Kyriopoulos, J. PY - 2015 DA - 2015// TI - Boceprevir for chronic genotype 1 hepatitis C virus in the current health care setting in Greece: a cost-effectiveness analysis JO - Clin Ther VL - 37 UR - https://doi.org/10.1016/j.clinthera.2015.05.003 DO - 10.1016/j.clinthera.2015.05.003 ID - Athanasakis2015 ER - TY - JOUR AU - Blázquez-Pérez, A. AU - San Miguel, R. AU - Mar, J. PY - 2013 DA - 2013// TI - Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients JO - Pharmacoeconomics VL - 31 UR - https://doi.org/10.1007/s40273-013-0080-3 DO - 10.1007/s40273-013-0080-3 ID - Blázquez-Pérez2013 ER - TY - JOUR AU - Brogan, A. J. AU - Talbird, S. E. AU - Thompson, J. R. AU - Miller, J. D. AU - Rubin, J. AU - Deniz, B. PY - 2014 DA - 2014// TI - Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0090295 DO - 10.1371/journal.pone.0090295 ID - Brogan2014 ER - TY - JOUR AU - Cammà, C. AU - Petta, S. AU - Cabibbo, G. AU - Ruggeri, M. AU - Enea, M. AU - Bruno, R. AU - Capursi, V. AU - Gasbarrini, A. AU - Alberti, A. AU - Craxì, A. PY - 2013 DA - 2013// TI - Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C JO - J Hepatol VL - 59 UR - https://doi.org/10.1016/j.jhep.2013.05.019 DO - 10.1016/j.jhep.2013.05.019 ID - Cammà2013 ER - TY - JOUR AU - Cammà, C. AU - Petta, S. AU - Enea, M. AU - Bruno, R. AU - Bronte, F. AU - Capursi, V. AU - Cicchetti, A. AU - Colombo, G. L. AU - Di Marco, V. AU - Gasbarrini, A. PY - 2012 DA - 2012// TI - Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C JO - Hepatology VL - 56 UR - https://doi.org/10.1002/hep.25734 DO - 10.1002/hep.25734 ID - Cammà2012 ER - TY - JOUR AU - Chan, K. AU - Lai, M. N. AU - Groessl, E. J. AU - Hanchate, A. D. AU - Wong, J. B. AU - Clark, J. A. AU - Asch, S. M. AU - Gifford, A. L. AU - Ho, S. B. PY - 2013 DA - 2013// TI - Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration JO - Clin Gastroenterol Hepatol VL - 11 UR - https://doi.org/10.1016/j.cgh.2013.05.014 DO - 10.1016/j.cgh.2013.05.014 ID - Chan2013 ER - TY - STD TI - Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs MBB, Esteban-Mur R, Elbasha EH. Cost-effectiveness of Boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health. 2013;16(6) https://doi.org/10.1016/j.jval.2013.1007.1006. ID - ref23 ER - TY - JOUR AU - Chhatwal, J. AU - Kanwal, F. AU - Roberts, M. S. AU - Dunn, M. A. PY - 2015 DA - 2015// TI - Cost-effectiveness and budget impact of hepatitis C virus treatment with Sofosbuvir and Ledipasvir in the United States JO - Ann Intern Med VL - 162 UR - https://doi.org/10.7326/M14-1336 DO - 10.7326/M14-1336 ID - Chhatwal2015 ER - TY - JOUR AU - Cortesi, P. A. AU - Mantovani, L. G. AU - Ciaccio, A. AU - Rota, M. AU - Mazzarelli, C. AU - Cesana, G. AU - Strazzabosco, M. AU - Belli, L. S. PY - 2015 DA - 2015// TI - Cost-effectiveness of new direct-acting antivirals to prevent post–liver transplant recurrent hepatitis JO - Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg VL - 15 UR - https://doi.org/10.1111/ajt.13320 DO - 10.1111/ajt.13320 ID - Cortesi2015 ER - TY - JOUR AU - Cure, S. AU - Bianic, F. AU - Gavart, S. AU - Curtis, S. AU - Lee, S. AU - Dusheiko, G. PY - 2014 DA - 2014// TI - Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavarin in previously untreated chronic hepatitis C genotype 1 patients JO - J Med Econ VL - 17 UR - https://doi.org/10.3111/13696998.2013.860033 DO - 10.3111/13696998.2013.860033 ID - Cure2014 ER - TY - JOUR AU - Cure, S. AU - Bianic, F. AU - Gavart, S. AU - Curtis, S. AU - Lee, S. AU - Dusheiko, G. PY - 2014 DA - 2014// TI - Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavarin in treatment-experienced chronic hepatitis C genotype 1 patients JO - J Med Econ VL - 17 UR - https://doi.org/10.3111/13696998.2013.844159 DO - 10.3111/13696998.2013.844159 ID - Cure2014 ER - TY - JOUR AU - Cure, S. AU - Guerra, I. AU - Dusheiko, G. PY - 2015 DA - 2015// TI - Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients JO - J Viral Hepat VL - 22 UR - https://doi.org/10.1111/jvh.12409 DO - 10.1111/jvh.12409 ID - Cure2015 ER - TY - JOUR AU - Cure, S. AU - Guerra, I. AU - Camma, C. AU - Craxi, A. AU - Carosi, G. PY - 2015 DA - 2015// TI - Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy JO - J Med Econ VL - 18 UR - https://doi.org/10.3111/13696998.2015.1040024 DO - 10.3111/13696998.2015.1040024 ID - Cure2015 ER - TY - JOUR AU - Dan, Y. Y. AU - Ferrante, S. A. AU - Elbasha, E. H. AU - Hsu, T. Y. PY - 2015 DA - 2015// TI - Cost-effectiveness of boceprevir co-administration versus pegylated interferon-alpha2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore JO - Antivir Ther VL - 20 ID - Dan2015 ER - TY - JOUR AU - Elbasha, E. H. AU - Chhatwal, J. AU - Ferrante, S. A. AU - El Khoury, A. C. AU - Laires, P. A. PY - 2013 DA - 2013// TI - Cost-effectiveness analysis of Boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal JO - Applied Health Economics and Health Policy VL - 11 UR - https://doi.org/10.1007/s40258-012-0007-8 DO - 10.1007/s40258-012-0007-8 ID - Elbasha2013 ER - TY - JOUR AU - Ferrante, S. A. AU - Chhatwal, J. AU - Brass, C. A. AU - El Khoury, A. C. AU - Poordad, F. AU - Bronowicki, J. -. P. AU - Elbasha, E. H. PY - 2013 DA - 2013// TI - Boceprevir for previously untreated patients with chronic hepatitis C genotype 1 infection: a US-based cost-effectiveness modeling study JO - BMC Infect Dis VL - 13 UR - https://doi.org/10.1186/1471-2334-13-190 DO - 10.1186/1471-2334-13-190 ID - Ferrante2013 ER - TY - JOUR AU - Gimeno-Ballester, V. AU - Mar, J. AU - San Miguel, R. PY - 2016 DA - 2016// TI - Cost–effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C JO - Expert Rev Pharmacoecon Outcomes Res VL - 16 UR - https://doi.org/10.1586/14737167.2015.1081061 DO - 10.1586/14737167.2015.1081061 ID - Gimeno-Ballester2016 ER - TY - JOUR AU - Hagan, L. M. AU - Sulkowski, M. S. AU - Schinazi, R. F. PY - 2014 DA - 2014// TI - Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals JO - Hepatology VL - 60 UR - https://doi.org/10.1002/hep.27151 DO - 10.1002/hep.27151 ID - Hagan2014 ER - TY - JOUR AU - Leleu, H. AU - Blachier, M. AU - Rosa, I. PY - 2015 DA - 2015// TI - Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C JO - J Viral Hepat VL - 22 UR - https://doi.org/10.1111/jvh.12311 DO - 10.1111/jvh.12311 ID - Leleu2015 ER - TY - JOUR AU - Linas, B. P. AU - Barter, D. M. AU - Leff, J. A. AU - Di Lorenzo, M. AU - Schackman, B. R. AU - Horsburgh, R. C. AU - Assoumou, S. A. AU - Salomon, J. A. AU - Weinstein, M. C. AU - Kim, A. Y. PY - 2014 DA - 2014// TI - The cost-effectiveness of improved HCV therapies in HIV/HCV co-infected individuals JO - AIDS (London, England) VL - 28 UR - https://doi.org/10.1097/QAD.0000000000000093 DO - 10.1097/QAD.0000000000000093 ID - Linas2014 ER - TY - JOUR AU - Linas, B. P. AU - Barter, D. M. AU - Morgan, J. R. AU - Pho, M. T. AU - Leff, J. A. AU - Schackman, B. R. AU - Horsburgh, C. R. AU - Assoumou, S. A. AU - Salomon, J. A. AU - Weinstein, M. C. PY - 2015 DA - 2015// TI - The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection JO - Ann Intern Med VL - 162 UR - https://doi.org/10.7326/M14-1313 DO - 10.7326/M14-1313 ID - Linas2015 ER - TY - JOUR AU - Liu, S. AU - Cipriano, L. E. AU - Holodniy, M. AU - Owens, D. K. AU - Goldhaber-Fiebert, J. D. PY - 2012 DA - 2012// TI - New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis JO - Ann Intern Med VL - 156 UR - https://doi.org/10.7326/0003-4819-156-4-201202210-00005 DO - 10.7326/0003-4819-156-4-201202210-00005 ID - Liu2012 ER - TY - JOUR AU - Liu, S. AU - Watcha, D. AU - Holodniy, M. AU - Goldhaber-Fiebert, J. D. PY - 2014 DA - 2014// TI - Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis JO - Ann Intern Med VL - 161 UR - https://doi.org/10.7326/M14-0602 DO - 10.7326/M14-0602 ID - Liu2014 ER - TY - JOUR AU - McEwan, P. AU - Ward, T. AU - Bennett, H. AU - Kalsekar, A. AU - Webster, S. AU - Brenner, M. AU - Yuan, Y. PY - 2015 DA - 2015// TI - Estimating the clinical and economic benefit associated with incremental improvements in sustained Virologic response in chronic hepatitis C JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0117334 DO - 10.1371/journal.pone.0117334 ID - McEwan2015 ER - TY - JOUR AU - Najafzadeh, M. AU - Andersson, K. AU - Shrank, W. H. AU - Krumme, A. A. AU - Matlin, O. S. AU - Brennan, T. AU - Avorn, J. AU - Choudhry, N. K. PY - 2015 DA - 2015// TI - Cost-effectiveness of novel regimens for the treatment of hepatitis C virus JO - Ann Intern Med VL - 162 UR - https://doi.org/10.7326/M14-1152 DO - 10.7326/M14-1152 ID - Najafzadeh2015 ER - TY - JOUR AU - Petta, S. AU - Cabibbo, G. AU - Enea, M. AU - Macaluso, F. S. AU - Plaia, A. AU - Bruno, R. AU - Gasbarrini, A. AU - Bruno, S. AU - Craxì, A. AU - Cammà, C. PY - 2014 DA - 2014// TI - Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C JO - Dig Liver Dis VL - 46 UR - https://doi.org/10.1016/j.dld.2014.06.009 DO - 10.1016/j.dld.2014.06.009 ID - Petta2014 ER - TY - JOUR AU - Petta, S. AU - Cabibbo, G. AU - Enea, M. AU - Macaluso, F. S. AU - Plaia, A. AU - Bruno, R. AU - Gasbarrini, A. AU - Craxì, A. AU - Cammà, C. PY - 2014 DA - 2014// TI - Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C JO - Hepatology VL - 59 UR - https://doi.org/10.1002/hep.27010 DO - 10.1002/hep.27010 ID - Petta2014 ER - TY - JOUR AU - Pfeil, A. M. AU - Reich, O. AU - Guerra, I. M. AU - Cure, S. AU - Negro, F. AU - Mullhaupt, B. AU - Lavanchy, D. AU - Schwenkglenks, M. PY - 2015 DA - 2015// TI - Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0126984 DO - 10.1371/journal.pone.0126984 ID - Pfeil2015 ER - TY - JOUR AU - Rein, D. B. AU - Wittenborn, J. S. AU - Smith, B. D. AU - Liffmann, D. K. AU - Ward, J. W. PY - 2015 DA - 2015// TI - The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus JO - Clin Infect Dis VL - 61 UR - https://doi.org/10.1093/cid/civ220 DO - 10.1093/cid/civ220 ID - Rein2015 ER - TY - JOUR AU - Saab, S. AU - Gordon, S. C. AU - Park, H. AU - Sulkowski, M. AU - Ahmed, A. AU - Younossi, Z. PY - 2014 DA - 2014// TI - Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection JO - Aliment Pharmacol Ther VL - 40 UR - https://doi.org/10.1111/apt.12871 DO - 10.1111/apt.12871 ID - Saab2014 ER - TY - STD TI - San Miguel R, Gimeno-Ballester V, Blazquez A, Mar J: Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C (Provisional abstract). In: Gut 2014: epub. ID - ref47 ER - TY - CHAP AU - Tice, A. AU - Ollendorf, D. A. AU - Pearson, S. D. PY - 2014 DA - 2014// TI - The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection, a technology assessment (final report) BT - USA: Institute for Clinical and Economic Review (California technology assessment Forum) ID - Tice2014 ER - TY - JOUR AU - Vellopoulou, A. AU - van Agthoven, M. AU - van der Kolk, A. AU - de Knegt, R. J. AU - Berdeaux, G. AU - Cure, S. AU - Bianic, F. AU - Lamotte, M. PY - 2014 DA - 2014// TI - Cost utility of Telaprevir–PR (Peginterferon–ribavirin) versus Boceprevir–PR and versus PR alone in chronic hepatitis C in the Netherlands JO - Applied Health Economics and Health Policy VL - 12 UR - https://doi.org/10.1007/s40258-014-0120-y DO - 10.1007/s40258-014-0120-y ID - Vellopoulou2014 ER - TY - JOUR AU - Warren, E. AU - Wright, A. AU - Jones, B. PY - 2014 DA - 2014// TI - Cost-effectiveness of Telaprevir in patients with genotype 1 hepatitis C in Australia JO - Value Health VL - 17 UR - https://doi.org/10.1016/j.jval.2014.07.011 DO - 10.1016/j.jval.2014.07.011 ID - Warren2014 ER - TY - JOUR AU - Westerhout, K. AU - Treur, M. AU - Mehnert, A. AU - Pascoe, K. AU - Ladha, I. AU - Belsey, J. PY - 2015 DA - 2015// TI - A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK national health service JO - J Med Econ VL - 18 UR - https://doi.org/10.3111/13696998.2015.1044457 DO - 10.3111/13696998.2015.1044457 ID - Westerhout2015 ER - TY - JOUR AU - Younossi, Z. M. AU - Park, H. AU - Saab, S. AU - Ahmed, A. AU - Dieterich, D. AU - Gordon, S. C. PY - 2015 DA - 2015// TI - Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection JO - Aliment Pharmacol Ther VL - 41 UR - https://doi.org/10.1111/apt.13081 DO - 10.1111/apt.13081 ID - Younossi2015 ER - TY - JOUR AU - Zhang, S. AU - Bastian, N. D. AU - Griffin, P. M. PY - 2015 DA - 2015// TI - Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US JO - BMC Gastroenterol VL - 15 UR - https://doi.org/10.1186/s12876-015-0320-4 DO - 10.1186/s12876-015-0320-4 ID - Zhang2015 ER - TY - JOUR AU - Crossan, C. AU - Tsochatzis, E. A. AU - Longworth, L. AU - Gurusamy, K. AU - Davidson, B. AU - Rodriguez-Peralvarez, M. AU - Mantzoukis, K. AU - O'Brien, J. AU - Thalassinos, E. AU - Papastergiou, V. PY - 2015 DA - 2015// TI - Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation JO - Health Technol Assess VL - 19 UR - https://doi.org/10.3310/hta19090 DO - 10.3310/hta19090 ID - Crossan2015 ER - TY - JOUR AU - Tsochatzis, E. A. AU - Crossan, C. AU - Longworth, L. AU - Gurusamy, K. AU - Rodriguez-Peralvarez, M. AU - Mantzoukis, K. AU - O'Brien, J. AU - Thalassinos, E. AU - Papastergiou, V. AU - Noel-Storr, A. PY - 2014 DA - 2014// TI - Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C JO - Hepatology VL - 60 UR - https://doi.org/10.1002/hep.27296 DO - 10.1002/hep.27296 ID - Tsochatzis2014 ER - TY - JOUR AU - Canavan, C. AU - Eisenburg, J. AU - Meng, L. AU - Corey, K. AU - Hur, C. PY - 2013 DA - 2013// TI - Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK JO - Dig Dis Sci VL - 58 UR - https://doi.org/10.1007/s10620-013-2705-y DO - 10.1007/s10620-013-2705-y ID - Canavan2013 ER - TY - JOUR AU - Liu, S. AU - Schwarzinger, M. AU - Carrat, F. AU - Goldhaber-Fiebert, J. D. PY - 2011 DA - 2011// TI - Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients JO - PLoS One VL - 6 UR - https://doi.org/10.1371/journal.pone.0026783 DO - 10.1371/journal.pone.0026783 ID - Liu2011 ER - TY - JOUR AU - Pol, S. AU - Bourliere, M. AU - Lucier, S. AU - Hezode, C. AU - Dorival, C. AU - Larrey, D. AU - Bronowicki, J. P. AU - Ledinghen, V. D. AU - Zoulim, F. AU - Tran, A. PY - 2017 DA - 2017// TI - Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients JO - J Hepatol VL - 66 UR - https://doi.org/10.1016/j.jhep.2016.08.021 DO - 10.1016/j.jhep.2016.08.021 ID - Pol2017 ER - TY - JOUR AU - Iyengar, S. AU - Tay-Teo, K. AU - Vogler, S. AU - Beyer, P. AU - Wiktor, S. AU - de Joncheere, K. AU - Hill, S. PY - 2016 DA - 2016// TI - Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis JO - PLoS Med VL - 13 UR - https://doi.org/10.1371/journal.pmed.1002032 DO - 10.1371/journal.pmed.1002032 ID - Iyengar2016 ER - TY - JOUR AU - Mesquita, F. AU - Santos, M. E. AU - Benzaken, A. AU - Corrêa, R. G. AU - Cattapan, E. AU - Sereno, L. S. AU - Naveira, M. C. M. PY - 2016 DA - 2016// TI - The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy JO - BMC Public Health VL - 16 UR - https://doi.org/10.1186/s12889-016-3784-4 DO - 10.1186/s12889-016-3784-4 ID - Mesquita2016 ER - TY - JOUR AU - Ward, T. AU - Gordon, J. AU - Bennett, H. AU - Webster, S. AU - Sugrue, D. AU - Jones, B. AU - Brenner, M. AU - McEwan, P. PY - 2016 DA - 2016// TI - Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences JO - Public Health VL - 141 UR - https://doi.org/10.1016/j.puhe.2016.08.002 DO - 10.1016/j.puhe.2016.08.002 ID - Ward2016 ER -